KR102397918B1 - Composition for skin improvement containing liquiritin apioside - Google Patents
Composition for skin improvement containing liquiritin apioside Download PDFInfo
- Publication number
- KR102397918B1 KR102397918B1 KR1020170037772A KR20170037772A KR102397918B1 KR 102397918 B1 KR102397918 B1 KR 102397918B1 KR 1020170037772 A KR1020170037772 A KR 1020170037772A KR 20170037772 A KR20170037772 A KR 20170037772A KR 102397918 B1 KR102397918 B1 KR 102397918B1
- Authority
- KR
- South Korea
- Prior art keywords
- skin
- composition
- formula
- present
- acceptable salt
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- FTVKHUHJWDMWIR-DTZHYSDLSA-N Liquiritin apioside Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1ccc([C@H]2Oc3c(C(=O)C2)ccc(O)c3)cc1)[C@H]1[C@@H](O)[C@@](O)(CO)CO1 FTVKHUHJWDMWIR-DTZHYSDLSA-N 0.000 title abstract description 35
- 230000006872 improvement Effects 0.000 title abstract description 25
- FTVKHUHJWDMWIR-FRFGAYJHSA-N (2s)-2-[4-[(2s,3r,4s,5s,6r)-3-[(2r,3s,4s)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-7-hydroxy-2,3-dihydrochromen-4-one Chemical compound O([C@H]1[C@H](OC=2C=CC(=CC=2)[C@H]2OC3=CC(O)=CC=C3C(=O)C2)O[C@@H]([C@H]([C@@H]1O)O)CO)[C@H]1OC[C@@](O)(CO)[C@@H]1O FTVKHUHJWDMWIR-FRFGAYJHSA-N 0.000 title abstract 4
- 239000002537 cosmetic Substances 0.000 claims abstract description 36
- 235000013305 food Nutrition 0.000 claims abstract description 23
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 23
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 18
- 210000003491 skin Anatomy 0.000 claims description 76
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000004480 active ingredient Substances 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 22
- -1 pack Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 12
- 239000006071 cream Substances 0.000 claims description 8
- 210000004927 skin cell Anatomy 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 7
- 238000004299 exfoliation Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 239000006210 lotion Substances 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000002585 base Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000008234 soft water Substances 0.000 claims description 2
- 230000000475 sunscreen effect Effects 0.000 claims description 2
- 239000000516 sunscreening agent Substances 0.000 claims description 2
- 239000013040 bath agent Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 32
- 210000000130 stem cell Anatomy 0.000 abstract description 32
- 230000036560 skin regeneration Effects 0.000 abstract description 27
- 230000036548 skin texture Effects 0.000 abstract description 23
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000004663 cell proliferation Effects 0.000 abstract description 9
- 102100028314 Filaggrin Human genes 0.000 abstract description 8
- 101710088660 Filaggrin Proteins 0.000 abstract description 8
- FTVKHUHJWDMWIR-DWMQJYMWSA-N Liquiritin apioside Chemical compound O([C@H]1[C@H](OC=2C=CC(=CC=2)[C@H]2OC3=CC(O)=CC=C3C(=O)C2)O[C@@H]([C@H]([C@@H]1O)O)CO)[C@@H]1OC[C@](O)(CO)[C@H]1O FTVKHUHJWDMWIR-DWMQJYMWSA-N 0.000 description 30
- NTDLXWMIWOECHG-YRCFQSNFSA-N apiin Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O[C@H]1[C@@H]([C@@](O)(CO)CO1)O)O)CO)C(C=1)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C=C1 NTDLXWMIWOECHG-YRCFQSNFSA-N 0.000 description 21
- 239000000306 component Substances 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- 235000013376 functional food Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 210000000434 stratum corneum Anatomy 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000654 additive Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 108010076876 Keratins Proteins 0.000 description 8
- 102000011782 Keratins Human genes 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 206010040844 Skin exfoliation Diseases 0.000 description 7
- 230000000996 additive effect Effects 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 229940061720 alpha hydroxy acid Drugs 0.000 description 6
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 6
- 210000002510 keratinocyte Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 238000000151 deposition Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 210000001047 desmosome Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000001339 epidermal cell Anatomy 0.000 description 3
- 210000002514 epidermal stem cell Anatomy 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 230000023895 stem cell maintenance Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000202807 Glycyrrhiza Species 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 2
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 2
- 108060003393 Granulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 235000020094 liqueur Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000008458 response to injury Effects 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- XJZYXTWSMDRIJE-UHFFFAOYSA-N 3,7-dihydropurin-6-one;sodium Chemical compound [Na].O=C1N=CNC2=C1NC=N2 XJZYXTWSMDRIJE-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 208000006981 Skin Abnormalities Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- XXWCODXIQWIHQN-UHFFFAOYSA-N butane-1,4-diamine;hydron;dichloride Chemical compound Cl.Cl.NCCCCN XXWCODXIQWIHQN-UHFFFAOYSA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Abstract
본 발명은 리퀴리틴 아피오시드를 포함하는 화장료 조성물에 관한 것으로, 본 발명의 리퀴리틴 아피오시드를 포함하는 화장료 조성물은 피부줄기세포 증식 또는 활성 촉진, 피부침착 개선 또는 필라그린 발현 촉진 효과가 우수하여, 피부재생용, 피부결 개선용 또는 피부보습용 화장료 조성물로서 사용할 수 있다. 또한, 본 발명의 리퀴리틴 아피오시드를 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The present invention relates to a cosmetic composition comprising liquiritin apioside, and the cosmetic composition comprising liquiritin apioside of the present invention has the effect of promoting skin stem cell proliferation or activity, improving skin adhesion, or promoting filaggrin expression. It is excellent, and can be used as a cosmetic composition for skin regeneration, skin texture improvement, or skin moisturizing. In addition, the composition containing liquiritin apioside of the present invention can be used as a food composition and a quasi-drug composition.
Description
본 발명은 리퀴리틴 아피오시드(Liquiritin apioside)를 포함하는 화장료 조성물에 관한 것으로서, 보다 상세하게는, 피부재생, 피부결개선 또는 보습 등의 우수한 효과를 가지는 화장료 조성물에 관한 것이다. 또한, 본 발명은 리퀴리틴 아피오시드를 포함하는 식품 조성물 및 의약외품 조성물에 관한 것이다.The present invention relates to a cosmetic composition containing liquiritin apioside, and more particularly, to a cosmetic composition having excellent effects such as skin regeneration, skin texture improvement or moisturizing. Further, the present invention relates to a food composition and a quasi-drug composition comprising liquiritin apioside.
피부재생은 손상에 대한 조직의 반응이며 조직회복의 과정으로, 주화성(chemotaxis), 세포의 분화 및 복제(differentiation and replication), 기질 단백질(matrix protein)의 합성, 혈관의 신생 및 창상의 재구성 등을 포함하는 복잡한 생물학적 과정이다(Steed, D.L. et al., Clin. Plast. Surg., 25:397(1998)).Skin regeneration is a tissue response to damage and is a process of tissue repair, such as chemotaxis, cell differentiation and replication, matrix protein synthesis, blood vessel angiogenesis and wound reconstitution, etc. It is a complex biological process involving (Steed, D.L. et al., Clin. Plast. Surg., 25:397 (1998)).
피부재생과 관련해 중요한 역할을 담당하는 줄기세포는 모낭(hair follicle)에 존재하는 것으로 알려져 있으며, 이들 세포의 일부는 모발과 표피의 재생과 성장에 중요한 역할을 수행하는 것으로 알려져 있다. 또한, 표피의 기저층(the basal cell layer of epidermis)에 존재하는 것으로 알려진 줄기세포는 표피와 진피층의 섬유아세포의 증식과 분화를 조절하여 피부재생과 건강에 중요한 역할을 수행하는 것으로 알려져 있다(Fuchis. Cell Stem Cell. 4(6):499, 2009).Stem cells that play an important role in skin regeneration are known to exist in hair follicles, and some of these cells are known to play an important role in the regeneration and growth of hair and epidermis. In addition, stem cells known to exist in the basal cell layer of the epidermis are known to play an important role in skin regeneration and health by regulating the proliferation and differentiation of fibroblasts in the epidermis and dermis (Fuchis. Cell Stem Cell. 4(6):499, 2009).
최근, 이러한 줄기세포를 피부재생에 이용하기 위하여, 피부세포나 다양한 줄기세포를 배양한 후 수거된 배양액이나 배양액의 분리된 분획물을 유효성분으로 화장품 조성물로 사용하려는 연구가 활발하게 진행되고 있고(Sauirkaya 외 3인, Turk J Vet Anim Sci 8:779, 2004), 실제로도 줄기세포 배양액을 이용하거나 배양액 유래 성분을 활용한 안티에이징(anti-aging) 제품이 다양하게 출시중에 있다. 그러나, 기존의 줄기세포 배지에는 화장품 원료로 허용되지 않는 염화콜린(Choline chloride), 히포크산틴 나트륨염(Hypoxanthine-sodium salt), 티미딘(Thymidine), 푸트레신 중염산염(Putrescine dihydrochloride), 질산 제2철(Ferric nitrate), L-글루타민(L-glutamin) 등의 성분이 포함되어 화장품의 조성물로 적합하지 않다는 문제점이 존재하고 있으며, 특히, 피부 줄기세포 배양액의 유효 성분들을 조합한 줄기세포 활성화 제품의 경우, 실제 배양액과 유사성이 부재하여 그로 인한 불충분 효과와, 여러 성분들을 사용하게 되면 단가가 증가하는 문제점이 존재하여, 여전히 피부 줄기세포의 활성화를 유도할 수 있으면서도 단일소재로 제조할 수 있는 화장료 조성물에 대한 개발 요구가 여전히 존재하고 있다.Recently, in order to use these stem cells for skin regeneration, studies are actively underway to use the separated fractions of the culture medium or the culture medium collected after culturing skin cells or various stem cells as an active ingredient as an active ingredient (Sauirkaya). 3 others, Turk J Vet Anim Sci 8:779, 2004), in fact, various anti-aging products using stem cell culture media or ingredients derived from culture media are on the market. However, choline chloride, hypoxanthine-sodium salt, thymidine, putrescine dihydrochloride, nitric acid that are not allowed as cosmetic raw materials in the existing stem cell medium There is a problem that it is not suitable as a cosmetic composition because it contains ingredients such as ferric nitrate and L-glutamin. In particular, stem cell activation by combining active ingredients of skin stem cell culture medium. In the case of the product, there is an insufficient effect due to the lack of similarity to the actual culture medium, and a problem in that the unit price increases when several components are used. There is still a need for development of cosmetic compositions.
피부는 피부 상층부터 표피, 진피, 피하 지방 층의 세 부분으로 분류된다. 이중 표피는 다시 각질층, 과립층, 유극층, 기저층으로 세분되며, 기저층의 표피 세포는 피부 상부로 올라오면서 분화되어, 최종적으로 각질층에 도달하게 된다. 각질층에 도달한 표피 세포는 핵이 소실되고, 케라틴(keratin)이라고 하는 불수용성 단백질로 채워지면서 죽은 세포로 전환된다. 각질층은 분화된 표피 세포(각질세포)와 이들 사이를 채워주는 피부 지질로 구성되는데, 이것은 체내 물질이 외부로 나가는 것을 막아주고, 외부의 물리적, 화학적 및 생물학적 자극으로부터 인체를 보호하는 방어 기능을 한다. 각질 세포는 데스모좀(desmosome)이라 하는 단백질에 의하여 연결되어 있고, 각질층 상부로 올라갈수록 데스모좀은 분해되어 각질 세포간 응집력이 약화되어, 결국 피부로부터 분리되어 떨어져 나간다. 정상 피부의 경우 각질층은 15 내지 20 개의 층으로 구성되고, 이들이 완전히 분리되는 턴오버(Turn-over) 기간은 정상적인 피부인 경우 대략 4주일이 걸린다. 그러나 노화피부, 건조피부, 여드름 피부 등은 각질층의 분리가 정상보다 늦어져 비정상적인 각질 세포가 생성되고 피부 표면에 쌓여 각질층이 두꺼워지며 거칠고 탄력이 떨어지게 된다. 또한, 외부 환경으로부터 자극받아 과생성된 멜라닌이 제대로 배출되지 않아 피부는 칙칙해진다.The skin is divided into three parts: the epidermis, the dermis, and the subcutaneous fat layer from the upper layer of the skin. The epidermis is further subdivided into the stratum corneum, granular layer, stratum corneum, and basal layer, and the epidermal cells of the basal layer are differentiated as they ascend to the top of the skin, and finally reach the stratum corneum. The epidermal cells that reach the stratum corneum lose their nuclei and are filled with an insoluble protein called keratin, turning into dead cells. The stratum corneum is composed of differentiated epidermal cells (keratinocytes) and the skin lipids that fill them, which prevents substances from entering the body and protects the human body from external physical, chemical and biological stimuli. . The keratinocytes are connected by a protein called desmosome, and as it goes up to the upper part of the stratum corneum, the desmosome is decomposed and the cohesive force between the keratinocytes is weakened, and eventually separates from the skin and falls off. In the case of normal skin, the stratum corneum consists of 15 to 20 layers, and the turn-over period during which they are completely separated takes approximately 4 weeks for normal skin. However, in aging skin, dry skin, acne skin, etc., the separation of the stratum corneum is delayed more than normal, and abnormal keratinocytes are generated and accumulated on the skin surface, the stratum corneum becomes thick and rough and elastic. In addition, the over-generated melanin stimulated by the external environment is not properly discharged, and the skin becomes dull.
내, 외적 요인에 의해 거칠어진 각질층은 각질 박리해주면 각질층 밑에 있는 세포의 활성 및 재생이 증가되어 피부가 투명하고 부드러워지는 효과를 얻을 수 있다.If the stratum corneum roughened by internal and external factors is exfoliated, the activity and regeneration of cells under the stratum corneum are increased, and the skin becomes transparent and soft.
현재, 각질 박리하는데 레티노산(Retinoic acid)과 알파 하이드록시산(alpha hydroxy acids, AHA)이 탁월한 효능을 보이는 것으로 알려져 있다. 이들의 각질박리 효과는 뛰어나나 실제적으로 상기의 미용효과를 얻으려면 알파히드록시산을 고농도(1.0~10%)로 함유하거나 강산성(pH 3.5 이하)을 유지하여야 한다. 그러나 고농도 혹은 강산성의 알파히드록시산을 함유한 화장료를 사용하는 경우, 홍반, 가려움, 따가움, 피부이상 또는 화상 등의 피부자극을 유발할 수 있으며, 태양광에 대한 민감성이 증가하여 결국 광독성과 광과민성 등의 피부자극이 발생할 수 있는 문제점이 존재한다.Currently, retinoic acid and alpha hydroxy acids (AHA) are known to show excellent efficacy in exfoliating dead skin cells. Although their exfoliating effect is excellent, in order to actually obtain the cosmetic effect, it is necessary to contain alpha-hydroxy acid at a high concentration (1.0 to 10%) or to maintain a strong acidity (pH 3.5 or less). However, when a cosmetic containing high concentration or strong acidic alpha hydroxy acid is used, it may cause skin irritation such as erythema, itchiness, stinging, skin abnormality, or burns. There is a problem that can cause skin irritation.
피부가 손상되면 염증반응에 이어 세포증식 과정이 진행되는데, 이는 피부가 손상된 후 2일부터 3주까지 지속된다. 이 시기에 섬유아세포는 콜라겐을 축적시켜 손상된 피부의 흠을 채우고, 섬유아세포의 증식을 유도하며, 상처부위에서는 새로운 세포와 간질성분의 재구성이 일어난다. 육아과정이라고도 불리는 이 증식과정은 상처발생 2일부터 3주까지 지속된다. 새로운 세포에 의한 어린 피부는 피부 세포의 활성이 활발하여 진피(dermis)의 섬유아세포(fibroblast)가 피부의 탄력 및 주름형성 억제에 중요한 콜라겐(collagen)의 합성과 신진대사가 왕성하다. 그리고 피부 보습에 필수적인 히아루론산(hyaluronic acid)을 포함한 당단백질류인 GAGs(Glucosaminoglycans) 합성도 활발하여 피부에 탄력, 보습 및 유연성을 부여한다. 또한 표피(epidermis)에서는 기저세포(basal layer cell)의 증식이 활발하고, 피부세포간의 결합을 강화시키는 라미닌, 인테그린, 데스모좀과 같은 결합단백질(adhesion protein)의 생성이 균형적으로 이루어져 세포조직을 강화시켜 건강한 피부를 유지해 준다.When the skin is damaged, an inflammatory response followed by a cell proliferation process, which lasts from 2 days to 3 weeks after the skin is damaged. During this period, fibroblasts accumulate collagen to fill in the flaws of damaged skin, induce proliferation of fibroblasts, and reorganize new cells and interstitial components in the wounded area. This proliferative process, also called the granulation process, lasts from 2 days to 3 weeks of wounding. In young skin by new cells, the activity of skin cells is active, and fibroblasts in the dermis are active in the synthesis and metabolism of collagen, which is important for skin elasticity and suppression of wrinkle formation. In addition, the synthesis of GAGs (Glucosaminoglycans), a glycoprotein containing hyaluronic acid, which is essential for moisturizing the skin, is also active, giving elasticity, moisture and flexibility to the skin. In addition, in the epidermis, the proliferation of basal layer cells is active, and the production of adhesion proteins such as laminin, integrin, and desmosome, which strengthens the bond between skin cells, is balanced, so that the cell tissue is restored. It strengthens and maintains healthy skin.
한편, 리퀴리틴 아피오시드(Liquiritin apioside)는 분자식 C26H30O13, 분자량 550.513을 가지는 화합물로서, 리퀴리티제닌-7-O-D-아피오실-4'-O-D-글루코사이드 또는 (2S)-7-(D-아피오-베타-D-퓨라노실옥시)-2-[4-(베타-D-글루코피라노실옥시)페닐]-2,3-디하이드로-4H-1-벤조피란-4-원으로 명명되며, 감초(Glycyrrhiza uralensis)의 주요 플라보노드 성분으로 알려져 있다. On the other hand, liquiritin apioside (Liquiritin apioside) is a molecular formula C 26 H 30 O 13 , as a compound having a molecular weight of 550.513, liquid ritijenin-7-OD-apiosyl-4'-OD-glucoside or (2S) -7-(D-apio-beta-D-furanosyloxy)-2-[4-(beta-D-glucopyranosyloxy)phenyl]-2,3-dihydro-4H-1-benzopyran Named as -4-one, it is known as a major flavonoid component of licorice ( Glycyrrhiza uralensis ).
이러한 배경하에, 본 발명자들은 피부재생, 피부결 개선 또는 보습 효과가 우수한 물질에 관하여 연구를 수행하였으며, 이에 리퀴리틴 아피오시드를 유효성분으로 포함하는 조성물이 피부줄기세포 증식 또는 활성 촉진 및 줄기세포성 유지, 피부침착 개선 또는 필라그린 발현 촉진 효과를 나타냄을 규명하여, 이를 활용한 화장료 조성물, 식품 조성물 및 의약외품 조성물을 완성하기에 이르렀다.Under this background, the present inventors conducted a study on a material having excellent skin regeneration, skin texture improvement, or moisturizing effect, and thus, a composition containing liquiritin apioside as an active ingredient promotes skin stem cell proliferation or activity and stems It was found that cellular maintenance, improvement of skin adhesion, or filaggrin expression promotion effect was identified, and a cosmetic composition, a food composition and a quasi-drug composition using the same were completed.
본 발명의 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition comprising, as an active ingredient, liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof.
구체적으로, 본 발명의 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부재생용 화장료 조성물을 제공하는 것이다.Specifically, it is an object of the present invention to provide a cosmetic composition for skin regeneration comprising, as an active ingredient, liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부결 개선용 화장료 조성물을 제공하는 것이다.Also, specifically, it is an object of the present invention to provide a cosmetic composition for improving skin texture comprising, as an active ingredient, liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof.
또한 구체적으로, 본 발명의 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부보습용 화장료 조성물을 제공하는 것이다.Also, specifically, it is an object of the present invention to provide a cosmetic composition for moisturizing the skin comprising liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 다른 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a food composition comprising, as an active ingredient, liqueuritin apioside represented by Formula 1 or a pharmaceutically acceptable salt thereof.
본 발명의 또 다른 목적은 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공하는 것이다.Another object of the present invention is to provide a quasi-drug composition comprising liqueuritin apioside represented by Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명은 상기와 같은 과제들을 해결하고, 본 발명의 목적을 달성하기 위하여 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition comprising a compound represented by Formula 1 or a cosmetically acceptable salt thereof in order to solve the above problems and achieve the object of the present invention.
구체적으로, 본 발명의 하나의 양태로서, 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부재생용 화장료 조성물을 제공한다.Specifically, as an aspect of the present invention, there is provided a cosmetic composition for skin regeneration comprising liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
구체적으로, 본 발명의 다른 하나의 양태로서, 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부결 개선용 화장료 조성물을 제공한다.Specifically, as another aspect of the present invention, there is provided a cosmetic composition for improving skin texture comprising, as an active ingredient, liqueuritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof.
또한 본 발명의 또 다른 하나의 양태로서, 화학식 1로 표시되는 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부보습용 화장료 조성물을 제공한다.Also, as another aspect of the present invention, there is provided a cosmetic composition for moisturizing the skin comprising liquiritin apioside represented by Formula 1 or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 하나의 양태로서, 리퀴리틴 아피오시드 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 식품 조성물을 제공한다.As another aspect of the present invention, there is provided a food composition comprising liqueuritin apioside or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 하나의 양태로서, 리퀴리틴 아피오시드 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 의약외품 조성물을 제공한다.As another aspect of the present invention, there is provided a quasi-drug composition comprising liqueuritin apioside or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에서는 하기 화학식 1로 표시되는 리퀴리틴 아피오시드 화합물 또는 이의 염을 포함하는 조성물을 제공한다.The present invention provides a composition comprising a liqueuritin apioside compound represented by the following Chemical Formula 1 or a salt thereof.
[화학식 1][Formula 1]
본 발명에 있어서, "리퀴리틴 아피오시드(liquiritin apioside)"는 상기 화학식 1로 표시되고, 분자식 C26H30O13, 분자량 550.513을 가지며, 리퀴리티제닌-7-O-D-아피오실-4'-O-D-글루코사이드 또는 (2S)-7-(D-아피오-베타-D-퓨라노실옥시)-2-[4-(베타-D-글루코피라노실옥시)페닐]-2,3-디하이드로-4H-1-벤조피란-4-원으로 명명되는 화합물로, 감초(Glycyrrhiza uralensis)의 주요 플라보노이드 성분으로 알려져 있다.In the present invention, "liquiritin apioside" is represented by Formula 1, molecular formula C 26 H 30 O 13 , has a molecular weight of 550.513, and liquiritin-7-OD-apiosyl- 4'-OD-glucoside or (2S)-7-(D-apio-beta-D-furanosyloxy)-2-[4-(beta-D-glucopyranosyloxy)phenyl]-2,3 -Dihydro-4H-1-benzopyran-4-one as a compound named, licorice ( Glycyrrhiza uralensis ) is known as a major flavonoid component.
본 발명은 리퀴리틴 아피오시드의 획득 방법에 특별히 한정되지 않으며, 당업계에 공지된 방법으로 화학적으로 합성하거나, 시판되는 물질을 사용할 수 있다.The present invention is not particularly limited to the method for obtaining liquiritin apioside, and may be chemically synthesized by a method known in the art or a commercially available material may be used.
본 발명의 화학식 1로 표시되는 리퀴리틴 아피오시드는 용매화된 형태뿐만 아니라 비-용매화된(unsolvated) 형태로 존재할 수도 있다. 본 발명의 리퀴리틴 아피오시드는 결정형 또는 무정형 형태로 존재할 수 있으며, 이러한 모든 물리적 형태는 본 발명의 범위에 포함된다.Liquiritin apioside represented by Formula 1 of the present invention may exist in a non-solvated form as well as a solvated form. Liquiritin apioside of the present invention may exist in crystalline or amorphous form, and all such physical forms are included in the scope of the present invention.
본 발명에 따른 조성물에 있어, 상기 리퀴리틴 아피오시드의 함량은 조성물 전체 중량 대비 0.0001 중량% 내지 10 중량%, 구체적으로는 0.0001 중량% 내지 1 중량%로 함유될 수 있으나, 이에 제한된 것은 아니다.In the composition according to the present invention, the content of liquiritin apioside may be contained in an amount of 0.0001 wt% to 10 wt%, specifically 0.0001 wt% to 1 wt%, based on the total weight of the composition, but is not limited thereto. .
본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 화장료 조성물을 제공한다. The present invention provides a cosmetic composition comprising the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 화장품학적으로 허용 가능한 염을 포함하는 피부재생용, 피부결 개선용 또는 피부보습용 화장료 조성물을 제공할 수 있다.In addition, specifically, the present invention may provide a cosmetic composition for skin regeneration, skin texture improvement, or skin moisturizing, comprising the compound represented by Formula 1 or a cosmetically acceptable salt thereof.
본 발명에 있어서, "피부재생"이라 함은 손상에 대한 조직의 반응 및 조직회복의 과정으로, 주화성(chemotaxis), 세포의 분화 및 복제(differentiation and replication), 기질 단백질(matrix protein)의 합성, 혈관의 신생 및 창상의 재구성 등을 포함하는 복잡한 생물학적 과정을 의미한다.In the present invention, "skin regeneration" refers to a process of tissue recovery and tissue response to damage, and includes chemotaxis, cell differentiation and replication, and matrix protein synthesis. , refers to complex biological processes including angiogenesis of blood vessels and reconstitution of wounds.
본 발명에 있어서, "피부결 개선"이라 함은 피부와 피부 사이의 간격이 늘어지고 골이 깊어져 거칠어졌거나, 미세한 주름, 기미, 주근깨 등으로 어두워지거나 붉어진 피부가 부드러워지고 피부톤이 밝아지는 것을 의미한다.In the present invention, "improving skin texture" means that the skin between the skin and the skin is stretched and the bone is deepened, so that the darkened or reddened skin becomes soft and the skin tone becomes brighter due to fine wrinkles, blemishes, freckles, etc. do.
구체적으로, 본 발명은 피부줄기세포 증식 또는 활성을 촉진하여 피부를 재생시키거나 피부결을 개선시킬 수 있으나 이에 한정된 것은 아니며, 또한, 각질 박리를 촉진하여 피부를 재생하거나 피부결을 개선시킬 수 있으나, 이에 한정된 것은 아니다.Specifically, the present invention may promote skin stem cell proliferation or activity to regenerate skin or improve skin texture, but is not limited thereto, and may also promote skin exfoliation to regenerate skin or improve skin texture. , but is not limited thereto.
본 발명에 있어서, "줄기세포"라 함은 태생기 전능세포(pluripotent cell)를 지칭하는 것으로, 어떤 조직으로든 발달할 수 있는 세포를 의미한다. "피부줄기세포(epidermal stem cell)"는 용어 그대로 피부에 존재하는 줄기세포로 어른에게도 존재하며, 주로 모낭이나 모낭의 내피세포, 분비선으로 분화되는 것으로 알려져 있다. 본 발명에서 구체적으로 상기 피부줄기세포는 인간 피부줄기세포(Human epidermal stem cell)일 수 있으나, 이에 한정된 것은 아니다. In the present invention, the term "stem cells" refers to embryonic pluripotent cells, and refers to cells that can develop into any tissue. "Epidermal stem cell" is a stem cell that exists in the skin as the term is, and exists in adults as well, and is known to be mainly differentiated into hair follicles, endothelial cells of hair follicles, and glands. Specifically, in the present invention, the skin stem cells may be human epidermal stem cells, but is not limited thereto.
본 발명에 있어서, "각질박리"라 함은 척추동물의 표피 부분을 이루는 케라틴(keratin) 성분인 각질을 벗겨내는 것을 의미하는 것으로, 본 발명의 일 실시예에서는, 리퀴리틴 아피오시드가 함유된 영양크림을 피부 침착 부위에 도포한 후 상기 침착된 부위의 피부가 개선되는 것을 확인함으로써, 본 발명의 리퀴리틴 아피오시드를 포함하는 화장료 조성물이 우수한 각질박리 용도가 있음을 확인하였다(표 3).In the present invention, "keratin exfoliation" refers to exfoliating the keratin, which is a component of the epidermis of vertebrates. In one embodiment of the present invention, liqueuritin apioside contains It was confirmed that the cosmetic composition containing liqueuritin apioside of the present invention has excellent keratin exfoliation use by confirming that the skin in the deposited area is improved after applying the nourishing cream to the skin deposit area (Table) 3).
본 발명의 일 실시예에서는, 리퀴리틴 아피오시드를 처리한 배지에서 배양된 피부줄기세포의 경우 대조군 대비 증식이 촉진되고, 줄기세포성(stemness)이 유지되는 효과가 우수하다는 것을 확인함으로써, 본 발명의 리퀴리틴 아피오시드를 포함하는 화장료 조성물이 피부재생 또는 피부결 개선 용도를 가지는 것을 확인하였다(표 1 및 표 2). In one embodiment of the present invention, in the case of skin stem cells cultured in a medium treated with liquiritin apioside, compared to the control group, proliferation is promoted and the effect of maintaining stemness is excellent. It was confirmed that the cosmetic composition comprising liqueuritin apioside of the present invention has a use for skin regeneration or skin texture improvement (Tables 1 and 2).
본 발명에 있어서, "피부보습"이란 피부에 수분감을 증가시켜주고, 촉촉한 상태를 유지시키는 것을 의미한다. 본 발명의 일 실시예에서는, 인간 각질세포주 HaCaT 세포의 배양배지에 리퀴리틴 아피오시드를 처리하였을 때 필라그린의 발현 정도가 아무것도 처리하지 않은 대조군 대비 더 우수하다는 것을 확인함으로써, 본 발명의 화학식 1로 표시되는 화합물 포함하는 조성물은 피부보습 용도로 사용될 수 있음을 확인하였다(표 4).In the present invention, "skin moisturization" means to increase the feeling of moisture in the skin and to maintain a moist state. In one embodiment of the present invention, it was confirmed that the expression level of filaggrin was superior to that of the control untreated when liquiritin apioside was treated in the culture medium of the human keratinocyte line HaCaT cells, so that the chemical formula of the present invention It was confirmed that the composition containing the compound represented by 1 can be used for skin moisturizing (Table 4).
본 발명에 따른 화장료 조성물은 용액, 외용연고, 크림, 폼, 영양화장수, 유연화장수, 팩, 유연수, 유액, 메이크업베이스, 에센스, 비누, 액체 세정료, 입욕제, 선 스크린크림, 선오일, 현탁액, 유탁액, 페이스트, 겔, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션, 패취 및 스프레이로 구성된 군으로부터 선택되는 제형으로 제조할 수 있으나, 이에 제한되는 것은 아니다.The cosmetic composition according to the present invention includes solutions, external ointments, creams, foams, nourishing lotions, softening lotions, packs, soft water, emulsions, makeup bases, essences, soaps, liquid detergents, bathing agents, sunscreen creams, sun oils, suspensions, Emulsion, paste, gel, lotion, powder, soap, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray can be prepared in a formulation selected from the group consisting of, but limited thereto it is not
또한, 본 발명의 화장료 조성물은 일반 피부 화장료에 배합되는 화장품학적으로 허용 가능한 담체를 1 종 이상 추가로 포함할 수 있으며, 통상의 성분으로 예를 들면 유분, 물, 계면활성제, 보습제, 저급 알콜, 증점제, 킬레이트제, 색소, 방부제, 향료 등을 적절히 배합할 수 있으나, 이에 제한되는 것은 아니다.In addition, the cosmetic composition of the present invention may further include one or more cosmetically acceptable carriers to be formulated in general skin cosmetics, and conventional ingredients include, for example, oil, water, surfactant, humectant, lower alcohol, A thickener, a chelating agent, a colorant, a preservative, a fragrance, etc. may be appropriately mixed, but the present invention is not limited thereto.
본 발명의 화장료 조성물에 포함되는 화장품학적으로 허용 가능한 담체는 제형에 따라 다양하다.The cosmetically acceptable carrier included in the cosmetic composition of the present invention varies depending on the formulation.
본 발명의 제형이 연고, 페이스트, 크림 또는 젤인 경우에는, 담체 성분으로서 동물성 유, 식물성 유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연 또는 이들의 혼합물이 이용될 수 있다.When the formulation of the present invention is an ointment, paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or Mixtures thereof may be used.
본 발명의 제형이 파우더 또는 스프레이인 경우에는, 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록사이드, 칼슘 실케이트, 폴리아미드 파우더 또는 이들의 혼합물이 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진제를 포함할 수 있다.When the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, or mixtures thereof may be used as a carrier component. In particular, in the case of a spray, additional chlorophyll propellants such as fluorohydrocarbons, propane/butane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는, 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되며, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알콜, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일이 이용될 수 있으며, 특히, 목화씨 오일, 땅콩 오일, 옥수수 배종 오일, 올리브오일, 피마자 오일 및 참깨 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 이용될 수 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylglycol oil may be used, and in particular, cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol fatty ester, fatty acid ester of polyethylene glycol or sorbitan may be used. there is.
본 발명의 제형이 현탁액인 경우에는, 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알콜, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, as a carrier component a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters; Crystalline cellulose, aluminum metahydroxide, bentonite, agar or tracanth may be used.
본 발명의 제형이 비누인 경우에는 담체 성분으로서 지방산의 알칼리 금속 염, 지방산 헤미에스테르 염, 지방산 단백질 히드롤리제이트, 이세티오네이트, 라놀린 유도체, 지방족 알콜, 식물성 유, 글리세롤, 당 등이 이용될 수 있다.When the formulation of the present invention is soap, alkali metal salts of fatty acids, fatty acid hemiester salts, fatty acid protein hydrolysates, isethionate, lanolin derivatives, aliphatic alcohols, vegetable oils, glycerol, sugar, etc. may be used as carrier components. can
본 발명의 다른 양태로서, 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 식품 조성물을 제공한다.As another aspect of the present invention, there is provided a food composition comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염을 포함하는 피부재생용, 피부결 개선용 식품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 "리퀴리틴 아피오시드 화합물", "피부재생", "피부결 개선" 및 “피부보습”은 상기에서 설명한 바와 같다. 상기 식품 조성물은 건강기능식품의 형태로 사용될 수 있으나, 이에 제한되는 것은 아니다.In addition, specifically, the present invention may provide a food composition for skin regeneration and skin texture improvement, comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. "Liquiritin apioside compound", "skin regeneration", "skin texture improvement" and "skin moisturizing" represented by Formula 1 are the same as described above. The food composition may be used in the form of a health functional food, but is not limited thereto.
본 발명의 식품 조성물에 포함된 화학식 1로 표시되는 화합물 또는 이의 식품학적으로 허용 가능한 염은 화학식 1로 표시되는 화합물을 포함하는 동식물, 이의 추출물, 이의 분획물 또는 이의 가공물의 형태로 포함될 수 있다. 또한 상기 조성물은 유효성분 이외에 식품학적으로 허용 가능한 식품보조첨가제를 포함할 수 있다.The compound represented by Formula 1 or a pharmaceutically acceptable salt thereof included in the food composition of the present invention may be included in the form of animals and plants, extracts thereof, fractions thereof, or processed products thereof including the compound represented by Formula 1. In addition, the composition may include a food pharmaceutically acceptable food supplement additive in addition to the active ingredient.
본 발명에 있어서, "식품보조첨가제"란 식품에 보조적으로 첨가될 수 있는 구성요소를 의미하며, 각 제형의 건강기능식품을 제조하는데 첨가되는 것으로서 당업자가 적절히 선택하여 사용할 수 있다. 식품보조첨가제의 예로는 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 충진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등이 포함되지만, 상기 예들에 의해 본 발명의 식품보조첨가제의 종류가 제한되는 것은 아니다.In the present invention, "food supplement additive" refers to a component that can be added to food as an auxiliary, added to the manufacture of health functional food of each formulation, and can be appropriately selected and used by those skilled in the art. Examples of food supplement additives include various nutrients, vitamins, minerals (electrolytes), synthetic flavoring agents and flavoring agents such as natural flavoring agents, coloring agents and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners , pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonation agent used in carbonated beverages, etc., but the above examples are not limited to the type of food supplement additive of the present invention.
본 발명의 식품 조성물에는 건강기능식품이 포함될 수 있다. 본 발명에 있어서, "건강기능식품"이란 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조 가능하며, 상기 제조시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 식품 조성물은 다양한 형태의 제형으로 제조될 수 있으며, 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 본 발명의 건강기능식품은 피부재생, 피부결 개선 또는 피부보습 효과를 증진시키기 위한 보조제로 섭취가 가능하다.The food composition of the present invention may include a health functional food. In the present invention, "health functional food" refers to food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. using raw materials or ingredients useful for the human body. Here, "functional" means to obtain useful effects for health purposes, such as regulating nutrients or physiological actions with respect to the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and during the manufacture, it can be prepared by adding raw materials and components commonly added in the art. In addition, the dosage form of the health functional food may be manufactured without limitation as long as it is a dosage form recognized as a health functional food. The food composition of the present invention can be prepared in various forms, and unlike general drugs, it has the advantage of not having side effects that may occur during long-term administration of the drug using food as a raw material, and has excellent portability, Health functional food can be taken as a supplement for skin regeneration, skin texture improvement, or skin moisturizing effect.
본 발명의 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있고, 기능성 식품 등 당업계에 알려진 용어와 혼용 가능하다. 아울러 본 발명의 건강기능식품은 당업자의 선택에 따라 식품에 포함될 수 있는 적절한 기타 보조성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화학식 1로 표시되는 화합물을 주성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함한다.There is no limitation in the form that the health functional food of the present invention can take, and it may include any food in a conventional sense, and may be used interchangeably with terms known in the art, such as functional food. In addition, the health functional food of the present invention can be prepared by mixing known additives with other suitable auxiliary ingredients that may be included in the food according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages and There are vitamin complexes, and the like, and it can be prepared by adding the compound represented by Formula 1 according to the present invention as a main component to juice, tea, jelly, juice, and the like. It also includes food used as feed for animals.
본 발명의 또 다른 양태로서, 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 의약외품 조성물을 제공한다.As another aspect of the present invention, there is provided a quasi-drug composition comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof.
또한, 구체적으로, 본 발명은 상기 화학식 1로 표시되는 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 피부줄기세포 증식 촉진 또는 피부재생용, 각질박리용 또는 피부보습용 의약외품 조성물을 제공할 수 있다. 상기 화학식 1로 표시되는 "리퀴리틴 아피오시드 화합물", "피부재생", "피부결 개선" 및 “피부보습”은 상기에서 설명한 바와 같다. In addition, specifically, the present invention can provide a quasi-drug composition for skin stem cell proliferation promotion or skin regeneration, keratin exfoliation, or skin moisturizing, comprising the compound represented by Formula 1 or a pharmaceutically acceptable salt thereof. . "Liquiritin apioside compound", "skin regeneration", "skin texture improvement" and "skin moisturizing" represented by Formula 1 are the same as described above.
본 발명의 의약외품 조성물에는 상기 성분 외에 필요에 따라 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 더욱 포함할 수 있다. 상기 약학적으로 허용 가능한 담체, 부형제 또는 희석제는 본 발명의 효과를 해하지 않는 한 제한되지 않으며, 예를 들어 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제, 윤활제, 감미제, 방향제, 보존제 등을 포함할 수 있다.The quasi-drug composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent if necessary in addition to the above components. The pharmaceutically acceptable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, and includes, for example, fillers, extenders, binders, wetting agents, disintegrants, surfactants, lubricants, sweeteners, fragrances, preservatives, etc. may include
본 발명의 약학적으로 허용 가능한 담체, 부형제 또는 희석제의 대표적인 예로는, 락토즈, 덱스트로스, 슈크로스, 솔비톨, 만니톨, 자일리톨, 말티톨, 전분, 젤라틴, 글리세린, 아카시아 고무, 알지네이트, 칼슘포스페이트, 칼슘카보네이트, 칼슘실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로즈, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 광물유, 프로필렌글리콜, 폴리에틸렌글리콜, 식물성 오일, 주사가능한 에스테르, 위텝솔, 마크로골, 트윈 61, 카카오지, 라우리지 등을 들 수 있다.Representative examples of the pharmaceutically acceptable carrier, excipient or diluent of the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, maltitol, starch, gelatin, glycerin, acacia gum, alginate, calcium phosphate, calcium Carbonate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, propylene glycol, polyethylene glycol, vegetable oil , injectable esters, Witepsol, Macrogol, Tween 61, cacao butter, laurage, and the like.
또한, 본 발명의 화학식 1로 표시되는 화합물을 의약외품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 피부재생, 피부결 개선 또는 피부보습용 성분을 포함할 수 있다. 추가적인 피부재생, 피부결 개선 또는 피부보습용 성분을 포함하게 되면 본 발명의 조성물의 피부재생, 피부결 개선 또는 피부보습 효과는 더욱 증가될 수 있다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 상기 의약외품 조성물은 당업계에 공지된 피부재생 성분; 당업계에 공지된 각질박리 성분으로서 레티노산(Retinoic acid)과 알파 하이드록시산(alpha hydroxy acids, AHA); 당업계에 공지된 피부탄력, 주름 개선 또는 보습성분으로서, 레티노산, TGF, 동물 태반 유래의 단백질, 베툴린산 및 클로렐라 추출물; 및 이들의 유도체와 각종 식물 추출물로 구성되는 군으로부터 선택되는 1종 또는 2종 이상의 성분을 추가로 포함할 수 있다. 추가 성분은 전체 조성물 중량에 대하여 0.0001 중량% 내지 10 중량%로 포함될 수 있으며, 상기 함량 범위는 피부 안전성, 상기 화학식 1로 표시되는 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있다.In addition, when the compound represented by Formula 1 of the present invention is used as a quasi-drug, it may further contain one or more active ingredients exhibiting the same or similar function. For example, it may contain a known component for skin regeneration, skin texture improvement, or skin moisturizing. When an additional component for skin regeneration, skin texture improvement or skin moisturizing is included, the skin regeneration, skin texture improvement or skin moisturizing effect of the composition of the present invention can be further increased. When adding the above ingredients, skin safety according to combined use, ease of formulation, and stability of active ingredients can be considered. The quasi-drug composition includes a skin regeneration component known in the art; Retinoic acid and alpha hydroxy acids (AHA) as exfoliating ingredients known in the art; As a skin elasticity, wrinkle improvement or moisturizing ingredient known in the art, retinoic acid, TGF, animal placenta-derived protein, betulinic acid and chlorella extract; and one or two or more components selected from the group consisting of derivatives thereof and various plant extracts. Additional components may be included in an amount of 0.0001 wt% to 10 wt% based on the total weight of the composition, and the content range may be adjusted according to requirements such as skin safety and ease of formulation of the compound represented by Formula 1 above.
본 발명의 의약외품 조성물은 소독 청결제, 샤워폼, 연고액, 물티슈, 코팅제 등을 예시할 수 있으나, 이에 제한되는 것이 아니며, 의약외품의 제제화 방법, 용량, 이용방법, 구성성분 등은 기술분야에 공지된 통상의 기술로부터 적절히 선택될 수 있다.The quasi-drug composition of the present invention may be exemplified by a disinfectant cleaner, shower foam, ointment, wet tissue, coating agent, etc., but is not limited thereto, and the formulation method of the quasi-drug, dosage, use method, components, etc. are known in the art. It may be appropriately selected from conventional techniques.
또한, 본 발명의 상기 화학식 1로 표시되는 화합물은 개체의 피부에 도포하는 단계를 포함하는, 피부재생, 피부결 개선 또는 피부보습 방법에 사용될 수 있다. 상기 개체는 쥐, 가축, 인간 등을 포함하는 포유동물을 제한 없이 포함할 수 있다.In addition, the compound represented by Formula 1 of the present invention can be used for skin regeneration, skin texture improvement, or skin moisturizing method, including applying to the skin of an individual. The subject may include, without limitation, mammals including mice, livestock, humans, and the like.
본 발명의 리퀴리틴 아피오시드 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 화장료 조성물은 피부줄기세포 증식 또는 활성 촉진, 줄기세포성 유지, 피부침착 개선 또는 필라그린 발현 촉진 효과가 우수하여, 피부재생용, 피부결 개선용 또는 피부보습용 화장료 조성물로서의 활용도가 높다. 또한, 본 발명의 리퀴리틴 아피오시드를 포함하는 조성물은 식품 조성물 및 의약외품 조성물로서 사용할 수 있다.The cosmetic composition comprising liquiritin apioside or a cosmetically acceptable salt thereof of the present invention as an active ingredient is excellent in promoting skin stem cell proliferation or activity, maintaining stem cell properties, improving skin adhesion, or promoting filaggrin expression Therefore, it has high utilization as a cosmetic composition for skin regeneration, skin texture improvement, or skin moisturizing. In addition, the composition containing liquiritin apioside of the present invention can be used as a food composition and a quasi-drug composition.
이하, 실시예를 통하여 본 발명의 구성 및 효과를 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것일 뿐 본 발명의 범위가 이들 실시예에 의해 제한되는 것은 아니다.Hereinafter, the configuration and effects of the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and the scope of the present invention is not limited by these examples.
참조예Reference example 1 : One : 리퀴리틴liqueur 아피오시드Apioside 물질 정보 substance information
[화학식 1][Formula 1]
물질명 : Liquiritin apiosideSubstance name: Liquiritin apioside
CAS No. : 74639-14-8CAS No. : 74639-14-8
분자식 : C26H30O13 Molecular Formula: C 26 H 30 O 13
분자량 : 550.513Molecular Weight: 550.513
구입처 : CHENGDU MUST BIO-TECHNOLOGY CO., LTDWhere to buy: CHENGDU MUST BIO-TECHNOLOGY CO., LTD
실험예Experimental example 1: One: 리퀴리틴liqueur 아피오시드를Apioside 처리한 processed 배지조건에서in the medium condition 배양된 cultured 피부줄기세포의skin stem cells 증식 촉진 및 줄기세포성 유지 효과에 따른 According to the effect of promoting proliferation and maintaining stem cell 피부줄기세포skin stem cells 증식 촉진 또는 피부재생 효과 Promoting proliferation or skin regeneration effect
1-1: 1-1: 무혈청serum free 배지조건에서in the medium condition 피부줄기세포skin stem cells 배양 culture
셀앤테크(Cellntec) 社에서 구입한 인간 피부줄기세포(Human epidermal stem cell)를 48-웰 플레이트(6×103 cells/well)에서 소태아혈청(fetal bovine serum)과 유사한 BPE(Bovine pituitary extract)가 첨가된 CNT-57 배지(Cellntec사)를 이용하여, 24 시간 동안 5% CO2 및 37℃ 조건에서 배양하였다. 그 후, 상기 배양액을 흡입관으로 제거한 다음, PBS 용액(GibcoBRL 社)을 이용하여 배지 성분을 제거하고, BPE가 포함되지 않은 CNT-57 배지에 리퀴리틴 아피오시드 10 ㎍/mL을 처리하여 5％ CO2 및 37℃ 조건에서 72 시간 동안 배양하였다. Human epidermal stem cells (BPE) similar to fetal bovine serum were used in 48-well plates (6×10 3 cells/well) purchased from Cellntec. Using the added CNT-57 medium (Cellntec), 5% CO 2 and cultured at 37° C. for 24 hours. Thereafter, the culture medium was removed through a suction tube, the medium components were removed using a PBS solution (GibcoBRL), and 10 μg/mL of liquiritin apioside was treated in CNT-57 medium not containing BPE. % CO 2 and incubated at 37° C. for 72 hours.
1-2: 1-2: CCKCCK -8 평가법을 통한 -8 through the evaluation method 피부줄기세포skin stem cells 증식 촉진 효과 확인 Confirmation of proliferation-promoting effect
상기 실시예 1-1에서 배양된 피부줄기세포를 하기와 같이 CCK-8(Cell counting kit-8) 평가를 실시하였다. 구체적으로, CCK-8 평가는 세포 내 전자전달계 내의 탈수소효소(Dehydrogenase)가 테트라졸리움 염(Tetrazolium Salt)을 분해하여 생성하는 포르마잔(Formazan)의 흡광도를 측정하여 살아있는 세포의 밀도를 간접적으로 나타내는 분석방법을 말한다. 보다 구체적으로, 세포에 CCK-8 용액(배지부피의 1/10을 처리)을 37℃에서 2 시간 동안 처리한 후, 파장 450 nm에서의 흡광도를 측정하였다. 그런 다음, 리퀴리틴 아피오시드의 피부줄기세포의 증식 촉진 효과를 하기의 증식율을 이용하여 측정된 흡광도 값으로부터 대조군인 CNT-57 배지 대비 증식율(%)을 구하여 계산한 후, 하기 표 1에 나타내었다. The skin stem cells cultured in Example 1-1 were evaluated with CCK-8 (Cell counting kit-8) as follows. Specifically, CCK-8 evaluation is an analysis that indirectly indicates the density of living cells by measuring the absorbance of Formazan, which is generated by dehydrogenase in the intracellular electron transport system by decomposing Tetrazolium Salt. say how More specifically, cells were treated with CCK-8 solution (treated with 1/10 of the medium volume) at 37° C. for 2 hours, and then absorbance at a wavelength of 450 nm was measured. Then, the proliferation-promoting effect of liquiritin apioside on skin stem cells was calculated by calculating the growth rate (%) compared to the control CNT-57 medium from the absorbance value measured using the following growth rate, and then indicated.
증식율(%) = (시료처리군의 흡광도/대조군의 흡광도) × 100 Growth rate (%) = (absorbance of sample treatment group / absorbance of control group) × 100
(liquiritin apioside)Liquiritin Apioside
(liquiritin apioside)
그 결과, 상기 표 1에서 확인한 바와 같이, 리퀴리틴 아피오시드를 처리한 배지에서 배양된 피부줄기세포의 경우, 리퀴리틴 아피오시드가 처리되지 않은 배지인 대조군 CNT-57 배지 대비 세포 증식율이 약 145%로 우수한 세포 증식 촉진 효과가 있음을 확인할 수 있었다. 이를 통해, 본 발명의 리퀴리틴 아피오시드를 유효성분으로 포함하는 화장료 조성물이 피부줄기세포의 증식을 촉진시키는 효과를 가지는 것을 확인함으로써, 피부재생 또는 피부결 개선 용도로 사용될 수 있음을 알 수 있었다.As a result, as confirmed in Table 1 above, in the case of skin stem cells cultured in a medium treated with liquiritin apioside, the cell proliferation rate compared to the control CNT-57 medium, which is a medium not treated with liquiritin apioside. It was confirmed that this drug had an excellent cell proliferation promoting effect at 145%. Through this, it can be seen that the cosmetic composition comprising liquiritin apioside of the present invention as an active ingredient can be used for skin regeneration or skin texture improvement by confirming that it has an effect of promoting the proliferation of skin stem cells. there was.
1-3: 1-3: 피부줄기세포의skin stem cells 줄기세포성 유지 효과 확인 Confirmation of stem cell maintenance effect
상기 실시예 1-1에서 배양된 피부줄기세포의 줄기세포성 유지 효과 확인을 위해 p63 발현 정도를 평가하였다. p63은 세포 내 전사인자로서 피부줄기세포의 유지 마커로 잘 알려져 있다. 구체적으로, 세포 RNA를 분리하여 cDNA를 합성한 다음, Taqman 염색액으로 실시간-PCR을 수행하여 p63의 발현 정도를 측정하였다. 본 실험에서의 RNA 농도는 S16 리보솜 RNA로 표준화하였으며, 실험 결과에서 나타나는 p63 증가 배수의 수치는 대조군인 CNT-57 배지 대비 배수를 의미한다. 그 결과는 하기 표 2와 같다. To confirm the stem cell maintenance effect of the skin stem cells cultured in Example 1-1, the expression level of p63 was evaluated. p63 is an intracellular transcription factor and is well known as a maintenance marker of skin stem cells. Specifically, cDNA was synthesized by isolating cellular RNA, and then real-time-PCR was performed with Taqman staining solution to measure the expression level of p63. The RNA concentration in this experiment was normalized to S16 ribosomal RNA, and the number of p63 increase folds in the experimental results means the fold compared to the control CNT-57 medium. The results are shown in Table 2 below.
줄기세포성(stemness) 유지 효과(반복수 = 3) Stemness maintenance effect (number of repetitions = 3)
(liquiritin apioside)Liquiritin Apioside
(liquiritin apioside)
그 결과, 상기 표 2에서 확인한 바와 같이, 리퀴리틴 아피오시드를 처리한 배지에서 배양된 피부줄기세포의 경우, p63의 증가 배수가 대조군인 CNT-57 배지보다 4.69배 증가하는 것을 확인할 수 있었다. 이러한 결과는, 본 발명의 리퀴리틴 아피오시드를 유효성분으로 포함하는 화장료 조성물이 줄기세포성 유지 효과가 우수하다는 것을 나타내는 것으로, 오랜 시간 동안 줄기세포성 효과를 유지하여 피부재생 또는 피부결 개선 효과가 지속됨을 시사하는 것이다. As a result, as confirmed in Table 2 above, in the case of skin stem cells cultured in a medium treated with liqueuritin apioside, it was confirmed that the fold increase of p63 increased by 4.69 times compared to the control CNT-57 medium. . These results indicate that the cosmetic composition comprising liquiritin apioside of the present invention as an active ingredient has an excellent stem cell maintenance effect, and maintains the stem cell effect for a long time to regenerate skin or improve skin texture This indicates that the effect lasts.
실험예Experimental example 2: 2: 피부침착skin irritation 개선 효과에 따른 according to the improvement effect 각질박리keratin exfoliation 효과 effect
건강한 20대에서 50대의 여성을 대상으로 리퀴리틴 아피오시드가 함유된 영양크림을 이용하여 각질 박리 효과를 확인해 보았다. The effect of exfoliating dead skin cells was confirmed by using a nourishing cream containing liqueuritin apioside for healthy women in their 20s to 50s.
구체적으로, 20세에서 50세까지의 여성 20명의 시험 부위에 DHA(Dihydroxyacetone, Sigma Aldrich, USA) 1.5% 용액을 8시간 동안 폐쇄첩포하여 침착시킨 후, 상기 리퀴리틴 아피오시드가 함유된 영양크림을 매일 2회 시험 부위에 도포하였다. 그런 다음, 도포 4일 후, 도포 8일 후, 도포 12일 후에 색도계(Chromameter CR-400, Minolta, Japan)를 이용하여 침착 부위의 피부 밝기에 대하여 측정하였고, 또한 DSLR을 이용하여 사진 촬영을 실시하였다. 측정값은 최대값과 최소값을 제외한 3회의 평균값을 구하여 평가하였으며, 침착 부위의 피부 밝기 개선이 높을수록 각질 박리 개선 효과가 있음을 나타낸다. 그 결과는 하기 표 3과 같다. Specifically, after depositing a 1.5% solution of DHA (Dihydroxyacetone, Sigma Aldrich, USA) with a closed patch for 8 hours on the test site of 20 women aged 20 to 50 years, the nutrient containing the liqueuritin apioside The cream was applied to the test site twice daily. Then, 4 days after application, 8 days after application, and 12 days after application, using a colorimeter (Chromameter CR-400, Minolta, Japan), the brightness of the skin at the deposition site was measured, and pictures were taken using a DSLR. did. The measured values were evaluated by obtaining the average value of three times excluding the maximum and minimum values, and the higher the improvement in skin brightness at the deposition site, the greater the effect of keratin exfoliation improvement. The results are shown in Table 3 below.
그 결과, 상기 표 3에서 확인한 바와 같이, 피부가 침착된 부위의 피부 밝기 개선율이 도포한 이후로 시간이 지남에 따라 점점 밝아지는 것을 확인할 수 있었으며, 특히, 도포 12일이 지난 이후에는 도포 4일 후보다 현저히 피부 침착 정도가 개선되는 것을 확인할 수 있었다. 이로써, 본 발명의 리퀴리틴 아피오시드를 유효성분으로 포함하는 화장료 조성물이 피부재생 또는 피부결 개선 용도, 특히, 각질박리 촉진에 의한 피부재생 또는 피부결 개선 용도로 사용될 수 있음을 알 수 있었다. As a result, as confirmed in Table 3, it was confirmed that the skin brightness improvement rate in the area where the skin was deposited gradually became brighter over time after application, and in particular, after 12 days of application, 4 days of application It was confirmed that the degree of skin deposition was significantly improved compared to the candidate. Accordingly, it was found that the cosmetic composition comprising liqueuritin apioside of the present invention as an active ingredient can be used for skin regeneration or skin texture improvement, in particular, for skin regeneration or skin texture improvement by promoting keratin exfoliation. .
실험예Experimental example 3: 3: 필라그린의of filaggrin 발현 촉진 효과에 따른 According to the expression promoting effect 피부보습skin moisturizing 효과 effect
리퀴리틴 아피오시드를 5 ㎍/mL, 또는 10 ㎍/mL가 되도록 하여 각각 인간 각질세포주 HaCaT 세포의 배양배지에 첨가하여 1일 동안 배양한 후, 세포로부터 RNA를 분리하고 cDNA를 합성하였다. Taqman 염색액으로 실시간-PCR을 수행하여 필라그린의 발현 정도를 측정하였다. 본 실험에서 RNA의 농도는 S16 리보솜 RNA로 표준화하였다 (반복수 = 3). 그 결과는 하기 표 4와 같다. Liquiritin apioside was added to the culture medium of the human keratinocyte line HaCaT cells at a concentration of 5 μg/mL or 10 μg/mL, respectively, and cultured for 1 day, then RNA was isolated from the cells and cDNA was synthesized. Real-time-PCR was performed with Taqman staining solution to measure the expression level of filaggrin. In this experiment, the concentration of RNA was normalized to S16 ribosomal RNA (number of repetitions = 3). The results are shown in Table 4 below.
그 결과, 표 4에서 확인한 바와 같이, 리퀴리틴 아피오시드를 처리한 경우, 아무것도 처리하지 않은 대조군 대비 필라그린의 증가배수가 농도의존적으로 증가하는 것을 확인할 수 있었다. 이로써, 본 발명의 리퀴리틴 아피오시드를 유효성분으로 함유하는 화장료 조성물이 피부보습 용도로 사용될 수 있음을 알 수 있었다.As a result, as confirmed in Table 4, it was confirmed that, when liqueuritin apioside was treated, the increase factor of filaggrin increased in a concentration-dependent manner compared to the control untreated with nothing. Accordingly, it was found that the cosmetic composition containing the liqueuritin apioside of the present invention as an active ingredient can be used for skin moisturizing.
Claims (12)
[화학식 1]
A cosmetic composition for moisturizing the skin comprising a compound represented by the following formula (1) or a cosmetically acceptable salt thereof as an active ingredient:
[Formula 1]
[화학식 1]
A cosmetic composition for exfoliating dead skin cells comprising a compound represented by the following formula (1) or a cosmetically acceptable salt thereof as an active ingredient:
[Formula 1]
According to claim 1 or 2, wherein the composition is a solution, external ointment, cream, foam, nourishing lotion, softening lotion, pack, soft water, emulsion, makeup base, essence, soap, liquid detergent, bath agent, sunscreen cream , sun oil, suspension, emulsion, paste, gel, lotion, powder, surfactant-containing cleansing, oil, powder foundation, emulsion foundation, wax foundation, patch and spray, characterized in that it has a formulation selected from the group consisting of a cosmetic composition.
[화학식 1]
A food composition for skin moisturizing comprising a compound represented by the following formula (1) or a food pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
[화학식 1]
[Formula 1]
[화학식 1]
A quasi-drug composition for skin moisturizing comprising a compound represented by the following formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:
[Formula 1]
[화학식 1]
[Formula 1]
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170037772A KR102397918B1 (en) | 2017-03-24 | 2017-03-24 | Composition for skin improvement containing liquiritin apioside |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170037772A KR102397918B1 (en) | 2017-03-24 | 2017-03-24 | Composition for skin improvement containing liquiritin apioside |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180108253A KR20180108253A (en) | 2018-10-04 |
| KR102397918B1 true KR102397918B1 (en) | 2022-05-13 |
Family
ID=63863036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170037772A KR102397918B1 (en) | 2017-03-24 | 2017-03-24 | Composition for skin improvement containing liquiritin apioside |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102397918B1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114032625B (en) * | 2021-11-01 | 2022-10-25 | 千芝雅(湖北)卫生用品有限公司 | Antibacterial material and application thereof in preparing adult menstrual period pants |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101218898B1 (en) * | 2010-04-27 | 2013-01-07 | 샘표식품 주식회사 | Composition for improving collagen synthesis |
| KR101599480B1 (en) * | 2014-08-04 | 2016-03-04 | 주식회사 콧데 | Composition for antiwrinkle, antiinflammatory and skin-whitening effect comprising liquiritin apioside) |
-
2017
- 2017-03-24 KR KR1020170037772A patent/KR102397918B1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180108253A (en) | 2018-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9028885B2 (en) | Composition for promoting adipocyte differentiation containing an extract of Rehmannia glutinosa, licorice, coicis semen, hordei fructus, chaenomelis fructus, Acanthopanacis cortex or Puerariae Radix | |
| KR20130022471A (en) | Cosmetic composition comprising camellia sinensis constituents | |
| JP5714869B2 (en) | Sugar-free pineapple extract, method for producing the same, and use thereof | |
| EP3097913B1 (en) | Cosmetic use of a hydroxypyranone derivative compound for promoting differentiation of adipocytes | |
| KR20230147028A (en) | Composition for anti-aging, anti-inflammation or skin regeneration containing Cannabis sativa stem extract as effective component | |
| JP6490342B2 (en) | Anti-skin aging agent containing Shiranui Chrysanthemum extract | |
| KR102397918B1 (en) | Composition for skin improvement containing liquiritin apioside | |
| TWI706792B (en) | Use of skunk cabbage extract or its fraction | |
| JP5259127B2 (en) | A composition for an integumental tissue containing at least a component derived from a plant belonging to the genus Ericaceae | |
| KR20180108251A (en) | Composition for skin improvement containing ligustroflavone | |
| KR102122649B1 (en) | Cosmetic composition comprising lactic acid and gluconolactone for enhancing skin barrier | |
| KR20160114018A (en) | Composition for improving skin | |
| CN106389141A (en) | Skin improving composition | |
| JP2021187787A (en) | Exosome secretagogue, exosome uptake promoter, exosome secretion-promoting beauty composition, and exosome secretion promoting method | |
| CN112584820A (en) | Cosmetic composition for skin moisture containing thyme complex extract as active ingredient | |
| KR101202006B1 (en) | Composition for healing the wound and improving the skin wrinkle comprising the vitamin u as active ingredient | |
| KR20180108254A (en) | Composition for skin improvement containing parishin A | |
| KR20180108255A (en) | Composition for skin improvement containing parishin B | |
| JP2020002053A (en) | Collagen production promoter, MMP inhibitor, melanin production inhibitor, cell growth promoter, antioxidant, wrinkle improver, pharmaceutical or food composition | |
| KR20180108252A (en) | Composition for skin improvement containing myricitrin | |
| KR102430512B1 (en) | Reelin/vegf-c production/activation promoter and skin external composition using the same | |
| KR102182710B1 (en) | Compositions for Skin Moisture Comprising Extract of Plectranthus tomentosa or Complex Extract thereof | |
| KR102326086B1 (en) | Composition for Improving Skin Conditions Having Skin Whitening, Moisturizing, Anti-Wrinkle and Skin Barrier Property Comprising Complex Extracts of Broussonetia kazinoki as Active Ingredient | |
| TW201800088A (en) | Composition for promoting adipocyte differentiation and method for screening materials for promoting adipocyte differentiation | |
| KR102490075B1 (en) | Cosmetic composition for wound healing or skin regeneration comprising extract of Selaginella tamariscina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |